Abstract：
UNASSIGNED: Benefits of docetaxel-based neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP) remain largely unknown. We explored whether docetaxel-based NCHT would bring pathological benefits and improve biochemical progression-free survival (bPFS) over neoadjuvant hormonal therapy (NHT) in locally advanced prostate cancer.
UNASSIGNED: A randomized trial was designed recruiting 141 locally advanced, high-risk prostate cancer patients who were randomly assigned at the ratio of 2:1 to the NCHT group (75 mg/m2 body surface area every 3 weeks plus androgen deprivation therapy for 6 cycles) and the NHT group (androgen deprivation therapy for 24 weeks). The primary end point was 3-year bPFS. Secondary end points were pathological response including pathological downstaging and minimal residual disease rates.
UNASSIGNED: The NCHT group showed significant benefits in 3-year bPFS compared to the NHT group (29% vs 9.5%, P = .002). At a median follow-up of 53 months, the NCHT group achieved a significantly longer median bPFS time than the NHT group (17 months vs 14 months). No significant differences were found between the 2 groups in pathological downstaging and minimal residual disease rates.
UNASSIGNED: NCHT plus RP achieved significant bPFS benefits when compared with NHT plus RP in high-risk, locally advanced prostate cancer. A larger cohort with longer follow-up duration is essential in further investigation.
UNASSIGNED: A randomized trial was designed recruiting 141 locally advanced, high-risk prostate cancer patients who were randomly assigned at the ratio of 2:1 to the NCHT group (75 mg/m2 body surface area every 3 weeks plus androgen deprivation therapy for 6 cycles) and the NHT group (androgen deprivation therapy for 24 weeks). The primary end point was 3-year bPFS. Secondary end points were pathological response including pathological downstaging and minimal residual disease rates.
UNASSIGNED: The NCHT group showed significant benefits in 3-year bPFS compared to the NHT group (29% vs 9.5%, P = .002). At a median follow-up of 53 months, the NCHT group achieved a significantly longer median bPFS time than the NHT group (17 months vs 14 months). No significant differences were found between the 2 groups in pathological downstaging and minimal residual disease rates.
UNASSIGNED: NCHT plus RP achieved significant bPFS benefits when compared with NHT plus RP in high-risk, locally advanced prostate cancer. A larger cohort with longer follow-up duration is essential in further investigation.
摘要：
■在根治性前列腺切除术（RP）之前，多西他赛为基础的新辅助化学激素治疗（NCHT）的益处仍然未知。我们探讨了基于多西他赛的NCHT是否比局部晚期前列腺癌的新辅助激素治疗（NHT）带来病理益处并改善生化无进展生存期（bPFS）。
■设计了一项随机试验，招募了141名本地高级人员，高危前列腺癌患者以2:1的比例随机分为NCHT组(每3周75mg/m2体表面积加6个周期雄激素剥夺治疗)和NHT组(24周雄激素剥夺治疗).主要终点为3年bPFS。次要终点是病理反应，包括病理降级和微小残留病率。
■与NHT组相比，NCHT组在3年bPFS中显示出显着的益处（29％vs9.5％，P=.002）。中位随访53个月,NCHT组的中位bPFS时间明显长于NHT组(17个月vs14个月).2组之间在病理降级和微小残留病率方面没有发现显着差异。
■NCHT加RP与NHT加RP相比，在高风险中取得了显着的bPFS收益，局部晚期前列腺癌.在进一步的调查中，更大的队列和更长的随访时间是必不可少的。
■设计了一项随机试验，招募了141名本地高级人员，高危前列腺癌患者以2:1的比例随机分为NCHT组(每3周75mg/m2体表面积加6个周期雄激素剥夺治疗)和NHT组(24周雄激素剥夺治疗).主要终点为3年bPFS。次要终点是病理反应，包括病理降级和微小残留病率。
■与NHT组相比，NCHT组在3年bPFS中显示出显着的益处（29％vs9.5％，P=.002）。中位随访53个月,NCHT组的中位bPFS时间明显长于NHT组(17个月vs14个月).2组之间在病理降级和微小残留病率方面没有发现显着差异。
■NCHT加RP与NHT加RP相比，在高风险中取得了显着的bPFS收益，局部晚期前列腺癌.在进一步的调查中，更大的队列和更长的随访时间是必不可少的。
